The Technical AnalystExchange: EURONEXT Sector: Healthcare Industry: Biotechnology
NFL Biosciences SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.40% €2.18
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.96 mill |
| EPS: | -0.550 |
| P/E: | -3.96 |
| Earnings Date: | Oct 05, 2023 |
| SharesOutstanding: | 9.61 mill |
| Avg Daily Volume: | 0.0606 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||
|---|---|---|---|---|
| 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||
| Ebit | n/a | |||
| Asset | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.96 | sector: PE 17.08 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.96 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€0.281 (-87.12%) €-1.899 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 2.02 - 2.34 ( +/- 7.34%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €2.18 (1.40% ) |
| Volume | 0.101 mill |
| Avg. Vol. | 0.0606 mill |
| % of Avg. Vol | 165.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALNFL.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALNFL.PA
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.